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Diabetic retinopathy (DR) is a retinal vascular 
disorder characterized by changes in the blood 
vessels of the retina that begins without symptoms 
and can advance to blurry vision, dark or floating 
spots, difficulty differentiating colors, and/
or problems focusing.1,2 Blindness and vision 
impairment in adults due to DR are highly prevalent 
and disabling conditions in the US, affecting at least 
3.3 million people over age 65.2-6  The number of 
people with DR will increase more than three-fold 
by 2050, creating an immense and costly public 
health problem.7-9 In 2004, for example, blindness 
from DR accounted for approximately $500 
million in direct medical costs, and exponentially 
more in indirect costs to society.10 Clinical trials 
demonstrating the efficacy of these treatments led 
the American Academy of Ophthalmology and the 
American Diabetes Association to recommend 
that all patients with diabetes have annual dilated 
fundus examinations (DFEs) to reduce their risk 
of vision loss.11,12 In addition, Healthy People 2010 
goals encourage 75% of all persons with diabetes 
to have a DFE.13  New effective treatment can also 
slow the rate of progression of retinopathy1.  Despite 
this fact, only 50% to 60% of adults with diabetes 
follow this recommendation and an estimated 50% 
of patients are diagnosed too late for treatment to 
be effective. 13-15
The Wills Eye Institute Department of Research 
is participating in a collaborative study with the 
Centers for Disease Control and Prevention along 
with other leading U.S. eye care institutions. One of 
the initiatives being tested is the use of a non-dilated 
eye screening program for people with diabetes, in 
a pharmacy-based setting. These screenings have 
the potential to improve health care outcomes and 
compliance by increasing access to eye care and 
earlier detection of diabetic retinopathy. 
Eye screenings are taking place at the outpatient 
pharmacy operated by the Thomas Jefferson 
University Hospital in Philadelphia. Before patients 
are screened, they complete a brief questionnaire 
to capture the patient’s past medical history, 
hemoglobin A1c levels, and current diabetes 
medications. The screening process takes less than 
ten minutes and consists of a visual acuity test, 
followed by a fundus photo (painless, non-dilated 
image of the retina taken with a Nidek camera). 
The images are sent electronically to the Wills Eye 
Department of Telemedicine and read by retina 
specialists. The final diagnosis and follow-up 
recommendations are mailed to the patient within 
two weeks. This technology has the potential to 
facilitate access to eye care for patients with diabetes, 
and to delay the progression to diabetic retinopathy. 
Furthermore, when located in a community 
pharmacy setting, this screening is very convenient 
for patients who are short on time or do not have the 
financial resources or health insurance to cover visits 
to a specialist. Since this eye screening does not 
require dilation of the pupils, minimal time is spent 
getting an eye exam.
While tele-opthalmology screenings hold promise 
for improving patient care, the utility of this 
technology in community settings depends on 
the volume of patients screened. The current 
study is being conducted in a pharmacy with an 
average of 1700 prescriptions filled weekly. Long-
term sustainability will depend on 1) whether 
or not insurance companies will add it to health 
care coverage, and 2) whether participating 
pharmacists are afforded the necessary time to 
contribute. To date, Wills Eye has screened a total 
of 143 patients; preliminary findings suggest that 
more than 10% of patients show signs of diabetic 
retinopathy (background diabetic retinopathy, 
proliferative diabetic retinopathy, pre-proliferative 
diabetic retinopathy, maculopathy or previous laser 
treatment). Early data also suggest that the camera 
has the potential to detect other eye abnormalities 
such as cataracts and hypertensive changes. These 
results provide incentive and purpose for future 
utilization of tele-opthalmology screenings. 
The program represents a novel model for 
engaging community pharmacists in a team 
approach to managing diabetes. Pharmacists 
are considered to be trusted health professionals 
and are generally very accessible. Specific actions 
taken by pharmacists involved in the program 
include: counseling patients on the importance 
of eye screening when they pick up their diabetes 
medications  and  providing continued reminders 
to the patient about the importance of following up 
with their physician about diabetes eye care. 
Data on the impact of the program, number 
of patients with DR, and outcomes are being 
collected. Primary measures include the impact 
of the screening in detecting DR and the rate of 
patient follow-up to an ophthalmologist for ocular 
pathology detection at the screening. If successful, 
the program has the potential to stimulate adoption 
of this emerging technology in other community 
pharmacy settings.  
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